CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) diagnosis, does nothing to reduce their risk of neurocognitive decline, stroke, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback